We use cookies on your browser to customize content for your viewing and for analytics. If you click “Accept” or continue to browse our website, we assume you have agreed to our use of cookies. For details, please refer to our Cookies Policy.
20 January
122
Pulnovo Medical has officially launched its 2025 global strategy with a breakthrough in the global multicenter clinical trial of Pulmonary Artery Denervation (PADN) for the treatment of pulmonary hypertension associated with left heart disease. The trial commenced at the Tbilisi Heart and Vascular Clinic in Georgia, with the successful enrollment of the first two patients. This marks a significant step in Pulnovo Medical’s journey towards global expansion, showcasing its innovative technological capabilities and growing international recognition.
The procedures were performed collaboratively by Professor Hang Zhang from Nanjing Hospital Affiliated with Nanjing Medical University and Professor George Khabeishvili from the Tbilisi Heart and Vascular Clinic. The successful operations provided tangible improvements for the patients, offering new hope for managing chronic heart failure and associated pulmonary hypertension.
Pulnovo Medical enters the new year with a clear vision and firm steps toward global milestones. Building on the successes of 2024, the company continues to prioritize innovation and international collaboration. Pulnovo Medical remains committed to connecting technology with care, bringing new hope to patients worldwide, and contributing to the prosperity of the global medical community.
About PADN
Pulmonary Artery Denervation (PADN) is a percutaneous pulmonary artery intervention procedure that uses a PADN catheter to deliver radiofrequency energy to the sympathetic nerves in the outer membrane of the pulmonary artery, resulting in the disappearance of the myelin sheath of the nerves and the fusion of the axons, which inhibits sympathetic activity, increases cardiac output, reduces pulmonary artery pressure , inhibits the pathologic remodeling of the pulmonary arteries, improves the patient's exercise endurance and cardiac function, and achieves long-term benefits from a single minimally invasive procedure.
About Pulnovo Medical
Founded in 2013, Pulnovo Medical Limited is a globally recognized leader in devices for the treatment of pulmonary hypertension and heart failure. Driven by innovation, Pulnovo is committed to advancing breakthrough technologies that offer therapeutic benefits to patients around the world.